ClinicalTrials.gg
Not yet recruitingNCT07472348INH-DILIUpdated Mar 16, 2026

Isoniazid-Related Hepatotoxicity in Clinical Practice: Incidence and Predictors

An observational study in Tuberculosis Infection and Tuberculosis Infection, Latent, sponsored by ASST Fatebenefratelli Sacco. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by ASST Fatebenefratelli Sacco · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
220
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this observational study is to determine how frequently isoniazid (INH) causes liver injury (hepatotoxicity) in adults treated for tuberculosis (TB) or latent tuberculosis infection (LTBI) and to understand which factors increase this risk. The study also aims to describe how hepatotoxicity is managed in real-world clinical practice and whether treatments such as corticosteroids can improve liver function tests.

The main questions this study aims to answer are:

  • How frequently does INH-induced hepatotoxicity occur in adults treated for TB or LTBI?
  • What demographic, clinical, microbiological, or lifestyle factors increase the risk of developing hepatotoxicity?
  • How do different management strategies, including treatment modification or the use of corticosteroids, affect liver recovery and completion of TB/LTBI therapy? This study does not involve experimental treatments. Researchers will analyze information already collected during routine clinical care, both retrospectively (from 2020 to 2025) and prospectively (2026-2028). There is no comparison group, but participants may have different clinical profiles or treatments, which will be compared to understand risk factors and outcomes.

Participants will:

  • Receive standard treatment for tuberculosis or LTBI, including isoniazid, as prescribed by their treating physicians.
  • Undergo routine assessments, such as blood tests, microbiology, imaging, and clinic visits, as part of their regular care.
  • Their clinical data will be recorded in the study database to analyze liver function trends, treatment changes, and outcomes.

The study will contribute to improving understanding of INH-induced hepatotoxicity and supporting safer and more effective treatment strategies for tuberculosis and LTBI.

Read the detailed description

Isoniazid (INH) is an essential drug for the treatment of tuberculosis (TB) and latent tuberculosis infection (LTBI), but it can cause liver damage in a subset of patients. The onset of liver toxicity is often unpredictable and can lead to treatment interruptions, alternative regimens, or incomplete therapy. Despite the widespread use of INH, real-world data describing the incidence, clinical characteristics, and management strategies of INH-induced hepatotoxicity remain limited, especially in European clinical settings.

This single-center, observational study will analyze adults treated for TB or LTBI who received INH as part of their therapeutic regimen. It combines a retrospective cohort (2020-2025) and a prospective cohort (2026-2028), allowing for the evaluation of both historical and current clinical practices. Clinical information already collected during routine care, including demographics, comorbidities, microbiological and imaging findings, anti-TB treatment details, and serial laboratory data, will be used to characterize the development and course of hepatotoxicity.

The study aims to describe the presentation of hepatotoxicity, how it is managed in routine clinical practice, and how clinical decisions, such as modifying antituberculosis therapy or the use of corticosteroids, influence liver recovery and treatment completion. INH-induced hepatotoxicity will be defined using internationally accepted criteria for drug-induced liver injury. Management strategies, including the use of corticosteroids, will be analyzed to understand their impact on biochemical resolution, safety, and treatment outcomes.

Because this is an observational study, no experimental interventions will be administered. All treatments, tests, and clinical decisions will follow standard tuberculosis and LTBI care provided by Luigi Sacco Hospital. Data will be pseudonymized and collected via the electronic case reporting form. The study is expected to provide evidence that can help optimize treatment strategies and support future clinical trials focused on safer management of INH-related liver injury.

02

Conditions studied

  • Tuberculosis Infection
  • Tuberculosis Infection, Latent

Keywords

  • Isoniazid
  • INH-induced hepatotoxicity
  • Drug-induced liver injury
  • Tuberculosis
  • Corticosteroid therapy
  • Observational study
  • Adverse drug reactions
03

In context

Latent Tuberculosis

200 studies on the registry are indexed under Latent Tuberculosis; 49 are open to participants now.

This study's planned enrollment of 220 is below the median of 260 across 82 observational studies indexed under Latent Tuberculosis.

Browse Latent Tuberculosis studies →

Lead sponsor

ASST Fatebenefratelli Sacco is the lead sponsor of 38 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study participants will be adults being treated for TB or LTBI at the Department of Infectious Diseases at Luigi Sacco Hospital in Milan, a regional referral center for TB management. The population includes individuals treated both inpatient and outpatient settings, whose clinical, laboratory, imaging, microbiological, and treatment data were routinely collected as part of standard care. The study comprises two sources: a retrospective cohort of adults treated with isoniazid between 2020 and 2025 and a prospective cohort enrolled between 2026 and 2028. Together, these groups represent the real-world patient population managed at this center for the treatment of TB and LTBI.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥18 years.
  • Patients diagnosed with TB or LTBI who received INH as part of their treatment regimen (either or second-line therapy), regardless of combination with other anti-TB drugs.
  • Normal baseline liver function tests (, AST and within reference range) and absence of clinical symptoms of liver dysfunction prior to initiation of anti-TB therapy.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Patients who did not receive isoniazid during their treatment course.
  • Pre-existing liver dysfunction, including biliary origin, before anti-TB therapy.
  • Pregnancy or lactation.
  • Concomitant use of non-TB hepatotoxic drugs.
  • Abnormal hepatic function on baseline laboratory testing.
  • Known INH resistance at treatment initiation.
  • Refusal to provide .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
220 participants (estimated)
Patient registry
No

Groups and cohorts

  • INH-treated Cohort

    Adults (≥18 years) diagnosed with tuberculosis (TB) or latent TB infection (LTBI) who received isoniazid as part of their standard treatment regimen. This cohort includes both retrospective participants (treated between 2020-2025) and prospective participants (2026-2028). No experimental interventions are administered; all treatments follow routine clinical care.

    Other: Standard isoniazid-based TB/LTBI therapy

Interventions

  • OtherStandard isoniazid-based TB/LTBI therapy

    Isoniazid administered as part of routine tuberculosis or latent tuberculosis infection treatment, according to standard clinical guidelines. The study observes real-world outcomes and does not assign or modify therapeutic regimens.

06

What researchers measure

Primary outcomes

  1. Incidence of isoniazid-induced hepatotoxicity in adults treated for TB or LTBI

    Proportion (%) of participants developing hepatotoxicity during treatment with isoniazid, defined according to international DILI criteria (ALT \>5× ULN and/or bilirubin \>3x ULN or ALT \>3× ULN and/or bilirubin \>2x ULN with symptoms). Unit of measure: Percentage of participants (%)

    Time frame: From treatment initiation to end of TB/LTBI therapy (approximately 6 to 12 months).

Secondary outcomes

  1. Risk factors for isoniazid-induced hepatotoxicity

    Identification of demographic, clinical, microbiological, and lifestyle factors associated with isoniazid-induced hepatotoxicity, including comorbidities (e.g., HIV infection and systemic diseases). Associations will be evaluated using multivariable regression models and reported as odds ratios with 95% confidence intervals. Unit of measure: Odds Ratio (OR)

    Time frame: During isoniazid treatment and up to 12 months after treatment initiation.

  2. Time to biochemical recovery after hepatotoxicity

    Time from the onset of isoniazid-induced hepatotoxicity to normalization of liver enzyme levels (ALT and bilirubin). Unit of measure: Time (days)

    Time frame: Up to 6 months after hepatotoxicity onset

  3. TB or TBI treatment completion

    Proportion of participants completing the planned TB or TBI treatment regimen despite the occurrence of hepatotoxicity. Unit of measure: Percentage of participants (%)

    Time frame: At the end of TB/TBI therapy (approximately 6-12 months).

  4. Effect of corticosteroid therapy on biochemical recovery

    Comparison of time to biochemical recovery between participants with hepatotoxicity treated with corticosteroids and those managed without corticosteroid therapy. Unit of measure: Time to recovery (days)

    Time frame: Up to 12 months after hepatotoxicity onset

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because the study uses clinical information collected during routine care, including sensitive health data subject to strict privacy regulations. Many participants in the retrospective cohort cannot be recontacted to obtain consent for data sharing, and the data include information that cannot be fully anonymized without compromising scientific validity. For these reasons, no IPD repository can be created, and access cannot be granted to external researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jul 2026, 2 months later.

Of 31 observational studies under Latent Tuberculosis, half reached primary completion within 94 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 98. This study's planned 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 16, 2026
StartEst.
May 30, 2026
Primary completionEst.
Jul 31, 2026
CompletionEst.
Sep 1, 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07472348
Lead sponsor
ASST Fatebenefratelli Sacco
Responsible party
Marco Schiuma (Medical Doctor, ASST Fatebenefratelli Sacco) — Principal investigator
First posted
Mar 16, 2026
Start date
May 30, 2026 (estimated)
Primary completion
Jul 31, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Mar 16, 2026

Study contacts

Marco Schiuma, MD
Contact
schiuma.marco@asst-fbf-sacco.it
+39 0239042685

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion